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Despite increased attention on prevention and early 
aggressive treatment with antibiotics and smart fluid 
resuscitation, there remains high morbidity and mortality 
from septic shock globally (1). Frequently septic patients 
develop persistent distributive shock that often requires 
vasopressor infusion to restore adequate mean arterial 
pressure (MAP) in order to provide adequate perfusion 
to critical organs and tissues. Although there are a variety 
of catecholamines available to increase blood pressure in 
these critically ill patients, the unmet need for additional 
therapies remains because of the persistently high morbidity 
and mortality of septic shock. 
Norepinephrine is the first line vasopressor in patients 
who do not respond to adequate fluid resuscitation (1). 
Recently there have been multiple randomized controlled 
trials (RCTs) of alternative non-catecholamine vasopressors 
including vasopressin (2,3), selepressin (4) and angiotensin 
II (5). Vasopressin is now considered the Surviving Sepsis 
Guidelines-recommended second vasopressor to be 
added to norepinephrine in refractory septic shock. This 
recommendation was based on multiple studies especially 
the pivotal Vasopressin and Septic Shock Trial (VASST) 
which added low dose vasopressin (0.01–0.04 units/hour) 
to ongoing norepinephrine compared to norepinephrine 
mono-therapy in septic shock. Although the 28-day 
mortality rates were similar, the vasopressin arm had lower 
mortality in those patients with less severe shock. However, 
recent studies have reported that the efficacy of vasopressin 
in clinical practice may be disappointing (6). Sacha and 
colleagues (6) reported a 45% response rate to vasopressin 
(defined by decreased catecholamine dose and stable blood 
pressure by six hours after initiation of vasopressin) and that 
patients treated after 12 hours and those with a high lactate 
had a lower response to vasopressin. There is also concern 
about potential vasopressin toxicity because vasopressin 
activates V2 receptors on endothelial cells (that can be 
prothrombotic) and in the renal collecting ducts (that can 
potentially decrease urine output. Those concerns are the 
rationale for assessing vasopressin-like agents that have 
more V1a agonism such as terlipressin or that are pure V1a 
agonists such as selepressin.
Terlipressin is a synthetic analogue of vasopressin 
which has greater affinity for the V1 receptor that is the 
mechanism of vascular smooth muscle vasoconstriction in 
response to vasopressin and thus could be associated with 
less side effects than vasopressin (7). Animal model studies 
have shown similar vasoconstrictive efficacy with terlipressin 
vs. vasopressin and less fluid retention with terlipressin 
which is critical for septic shock patients. 
Terlipressin has been primarily studied in critically 
ill patients with hepatorenal syndrome and small studies 
have demonstrated improved renal function in these 
challenging patients. However, there is equipoise around 
use of terlipressin or norepinephrine in septic shock (8-14). 
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Liu and colleagues addressed this question by conducting 
a multicenter, RCT of terlipressin vs. norepinephrine in 
septic shock in China (15). They are to be commended 
for their efforts in implementing a large pivotal RCT in 
a country which historically has not performed such large 
RCTs in critical care.
They randomized 617 patients to terlipressin (n=312) or 
norepinephrine infusion (n=305) plus standard care which 
included open label vasopressors. They used an a priori 
modified intent-to-treat primary analysis of the primary 
endpoint, 28-day mortality in a subgroup (terlipressin 
n=260; norepinephrine n=266). There was no difference in 
28-day mortality (terlipressin =40%, norepinephrine =38%, 
p NS). Selected secondary endpoints such as days alive and 
free of vasopressors and change in Sepsis Organ Failure 
Assessment (SOFA) score did not differ between groups. 
However, there were more serious adverse events in the 
terlipressin than the norepinephrine group (30% vs. 12%, 
P<0.01).
The authors conclude that there is no difference in 
mortality between terlipressin and norepinephrine but that 
terlipressin has more serious adverse events.
This RCT was powered for mortality and the main result 
was negative suggesting that the result in a true negative. 
However, the assumed mortality rates and absolute risk 
reduction [identical to what was used on the VASST (3)] 
are quite high for the period of the RCT conduct. The 
mortality rates in the norepinephrine were higher than 
reported in recent RCTs in septic shock such as early goal-
directed therapy (16-19); that is somewhat surprising. The 
trial was also stopped at the second interim analysis because 
of the a priori futility analysis. 
Terlipressin and norepinephrine were administered 
as continuous infusions of 20–160 mg/h. terlipressin or 
4–30 mg/min. norepinephrine (a low to moderate dose of 
norepinephrine) to achieve a target MAP of 65–75 mmHg. 
Terlipressin is often initiated with a bolus followed by an 
infusion but this was not done in the current RCT and 
that may have limited the beneficial effects of terlipressin 
reported in prior studies (20). In both groups, the bedside 
nurse could also administer open label norepinephrine, 
dopamine or epinephrine to achieve target MAP. 
Study drug was weaned when the patient had been 
hemodynamically stable for 12 hours, a reasonable aspect 
of the protocol. The study drug could be withheld if a pre-
defined serious adverse event occurred. If a patient was 
weaned off study drug and later redeveloped septic shock, 
then the assigned blinded study drug was restarted during 
the same ICU admission.
The inclusion criteria were septic shock defined as 
hypotension despite “adequate” fluid resuscitation (not 
defined as to volume or type of fluid). The MAP during the 
treatment period was remarkably high, about 80 mmHg, 
i.e., higher than the target MAP of 65–75 mmHg (Liu et al., 
Figure 2).
The use of short term (28-day) mortality for septic shock 
interventions has existed for decades but recent authors 
have questioned the validity of such a hard endpoint and 
have argued for more creative endpoints similar to the field 
of cardiology. Recently the United States Food and Drug 
Administration approved angiotensin II for the treatment 
of septic shock (5). There has been discussion of the FDA 
rationale for approving angiotensin II using and approving a 
novel primary endpoint of MAP elevation at three hours (21). 
These investigators should be congratulated for 
conducting a high-quality trial, with an interesting design, 
incorporating a blinded placebo infusion in what is a 
challenging research area. The strengths of the study 
include well-matched patients modified intent-to-treat 
primary analyses, and the method for organ dysfunction 
analyses (22). 
What are the wider implications of the Liu’s RCT? 
Prior  RCTs establ ish that  norepinephrine is  the 
vasopressor of first choice and that vasopressin may be 
added but that dopamine should be avoided because of 
early vasopressin (2) vs. norepinephrine, norepinephrine 
vs. epinephrine (23), norepinephrine vs. dopamine (24) 
and vasopressin vs. norepinephrine in septic shock (3). 
A recent propensity matched cohort study (25) from the 
VASST coordinating center showed that lower doses 
of vasopressin were associated with similar outcomes 
compared to NE. Patients who received early vasopressin 
and norepinephrine increased MAP to the target of 
65 mmHg faster than those receiving norepinephrine 
monotherapy (26).
For the clinician we agree with Liu and colleagues that 
there is no difference in mortality between terlipressin 
and norepinephrine but that terlipressin has more 
serious adverse events. Thus, norepinephrine remains 
the vasopressor of first choice but that vasopressin or 
terlipressin could be added to patients with refractory septic 
shock who do not respond to norepinephrine.
Acknowledgements
Dr. Russell reports having received an investigator-
S1272
© Journal of Thoracic Disease. All rights reserved.   J Thorac Dis 2019;11(Suppl 9):S1270-S1273 | http://dx.doi.org/10.21037/jtd.2019.05.07
Williams and Russell. Terlipressin in septic shock
initiated grant from Grifols (entitled “Is HBP a mechanism 
of albumin’s efficacy in human septic shock?”) that was 
provided to and administered by UBC.
Footnote
Conflicts of Interest: Dr. Williams reports consulting fees 
in the last 3 years from Ferring (selepressin), AKPA 
(recombinant soluble thrombomodulin) and Lajolla 
Pharmaceuticals (angiotensin II). Dr. Russell reports patents 
owned by the University of British Columbia (UBC) that 
are related to the use of PCSK9 inhibitor(s) in sepsis and 
related to the use of vasopressin in septic shock. Dr. Russell 
is an inventor on these patents. Dr. Russell was a founder, 
Director and shareholder in Cyon Therapeutics Inc. Dr. 
Russell is a shareholder in Molecular You Corp (in the last 
36 months). Dr. Russell reports receiving consulting fees 
in the last 3 years from: (I) Asahi Kesai Pharmaceuticals of 
America (AKPA) (developing recombinant thrombomodulin 
in sepsis). (II) SIB Therapeutics LLC (developing a 
sepsis drug). (III) Ferring Pharmaceuticals (manufactures 
vasopressin and developing selepressin).
References
1. Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis 
Campaign: International Guidelines for Management 
of Sepsis and Septic Shock: 2016. Crit Care Med 
2017;45:486-552.
2. Gordon AC, Mason AJ, Thirunavukkarasu N, et al. Effect 
of Early Vasopressin vs Norepinephrine on Kidney Failure 
in Patients With Septic Shock: The VANISH Randomized 
Clinical Trial. JAMA 2016;316:509-18.
3. Russell JA, Walley KR, Singer J, et al. Vasopressin versus 
norepinephrine infusion in patients with septic shock. N 
Engl J Med 2008;358:877-87.
4. Russell JA, Vincent JL, Kjolbye AL, et al. Selepressin, a 
novel selective vasopressin V1A agonist, is an effective 
substitute for norepinephrine in a phase IIa randomized, 
placebo-controlled trial in septic shock patients. Crit Care 
2017;21:213.
5. Khanna A, English SW, Wang XS, et al. Angiotensin II 
for the Treatment of Vasodilatory Shock. N Engl J Med 
2017;377:419-30.
6. Sacha GL, Lam SW, Duggal A, et al. Predictors of 
response to fixed-dose vasopressin in adult patients with 
septic shock. Ann Intensive Care 2018;8:35.
7. Rehberg S, Ertmer C, Lange M, et al. Role of selective 
V2-receptor-antagonism in septic shock: a randomized, 
controlled, experimental study. Crit Care 2010;14:R200.
8. Lange M, Ertmer C, Rehberg S, et al. Effects of 
two different dosing regimens of terlipressin on 
organ functions in ovine endotoxemia. Inflamm Res 
2011;60:429-37.
9. Morelli A, Ertmer C, Pietropaoli P, et al. Terlipressin: a 
promising vasoactive agent in hemodynamic support of 
septic shock. Expert Opin Pharmacother 2009;10:2569-75.
10. Morelli A, Ertmer C, Rehberg S, et al. Continuous 
terlipressin versus vasopressin infusion in septic shock 
(TERLIVAP): a randomized, controlled pilot study. Crit 
Care 2009;13:R130.
11. Rehberg S, Ertmer C, Kohler G, et al. Role of arginine 
vasopressin and terlipressin as first-line vasopressor agents 
in fulminant ovine septic shock. Intensive Care Med 
2009;35:1286-96.
12. Westphal M, Rehberg S, Ertmer C, et al. Terlipressin--
more than just a prodrug of lysine vasopressin? Crit Care 
Med 2009;37:1135-6.
13. Morelli A, Ertmer C, Lange M, et al. Effects of short-term 
simultaneous infusion of dobutamine and terlipressin in 
patients with septic shock: the DOBUPRESS study. Br J 
Anaesth 2008;100:494-503.
14. Morelli A, Ertmer C, Westphal M. "Terlipressin in the 
treatment of septic shock: the earlier the better"? Best 
Pract Res Clin Anaesthesiol 2008;22:317-21.
15. Liu ZM, Chen J, Kou Q, et al.  Terlipressin versus 
norepinephrine as infusion in patients with septic shock: 
a multicentre, randomised, double-blinded trial. Intensive 
Care Med 2018;44:1816-25.
16. Angus DC. Early, Goal-Directed Therapy for Septic 
Shock - A Patient-Level Meta-Analysis. N Engl J Med 
2017;377:995.
17. ARISE Investigators; ANZICS Clinical Trials Group, 
Peake SL, et al. Goal-directed resuscitation for patients 
with early septic shock. N Engl J Med 2014;371:1496-506.
18. PRISM Investigators, Rowan KM, Angus DC, et al. Early, 
Goal-Directed Therapy for Septic Shock - A Patient-Level 
Meta-Analysis. N Engl J Med 2017;376:2223-34.
19. Yende S, Thompson BT. Evaluating Glucocorticoids for 
Sepsis: Time to Change Course. JAMA 2016;316:1769-71.
20. Serpa Neto A, Nassar AP, Cardoso SO, et al. Vasopressin 
and terlipressin in adult vasodilatory shock: a systematic 
review and meta-analysis of nine randomized controlled 
trials. Crit Care 2012;16:R154.
21. Senatore F, Jagadeesh G, Rose M, et al. FDA Approval 
of Angiotensin II for the Treatment of Hypotension in 
S1273Journal of Thoracic Disease, Vol 11, Suppl 9 May 2019
© Journal of Thoracic Disease. All rights reserved.   J Thorac Dis 2019;11(Suppl 9):S1270-S1273 | http://dx.doi.org/10.21037/jtd.2019.05.07
Adults with Distributive Shock. Am J Cardiovasc Drugs 
2019;19:11-20.
22. Russell JA, Lee T, Singer J, et al. Days alive and free as an 
alternative to a mortality outcome in pivotal vasopressor 
and septic shock trials. J Crit Care 2018;47:333-7.
23. Myburgh JA, Higgins A, Jovanovska A, et al. A comparison 
of epinephrine and norepinephrine in critically ill patients. 
Intensive Care Med 2008;34:2226-34.
24. De Backer D, Biston P, Devriendt J, et al. Comparison of 
dopamine and norepinephrine in the treatment of shock. 
N Engl J Med 2010;362:779-89.
25. Russell JA, Wellman H, Walley KR. Vasopressin versus 
norepinephrine in septic shock: a propensity score matched 
efficiency retrospective cohort study in the VASST 
coordinating center hospital. J Intensive Care 2018;6:73.
26. Hammond DA, Ficek OA, Painter JT, et al. Prospective 
Open-label Trial of Early Concomitant Vasopressin and 
Norepinephrine Therapy versus Initial Norepinephrine 
Monotherapy in Septic Shock. Pharmacotherapy 
2018;38:531-8.
Cite this article as: Williams MD, Russell JA. Terlipressin 
or norepinephrine in septic shock: do we have the answer? 
J Thorac Dis 2019;11(Suppl 9):S1270-S1273. doi: 10.21037/
jtd.2019.05.07
